The Phase I Study of Recombinant Human Nerve Growth Factor Injection
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, single/multiple dose study of recombinant
human nerve growth factor injection in healthy Chinese volunteers on safety, tolerability and
pharmacokinetics